3SBio's Unit Gets Exclusive Commercialization Rights for Clifutinib Besylate in Mainland China

MT Newswires04:02 ET

3SBio Partners With Sunshine Lake Pharma for Drug Rights

TipRanksNov 25 05:17 ET

3sbio (01530.HK): Shenyang 3sbio and guangdong hec technology holding reached a cooperation on sulfonamic acid clifene.

Gelonghui November 25th | 3sbio (01530.HK) announced that its subsidiary Shenyang 3sbio Pharmaceutical Co., Ltd. has reached a cooperation agreement with Guangdong Hec CJ Pharm Co., Ltd. and its subsidiary Yichang Hec CJ Pharm Co., Ltd. on the commercialization of specific indications of Benzoate Crizotinib. According to the agreement, Shenyang 3sbio will obtain the exclusive commercialization rights of Crizotinib specific indications under the product portfolio of Guangdong Hec CJ Pharm in mainland China. Shenyang 3sbio will make the initial payment and corresponding R&D and sales milestone payments to Guangdong Hec CJ Pharm as agreed in the agreement. Guangdong Hec CJ Pharm will continue to be responsible for the Crizotinib

Gelonghui FinanceNov 25 05:03 ET

Express News | 3Sbio - Cooperation Between Shenyang Sunshine and Sunshine Lake Pharma in Respect of Clifutinib Besylate

ReutersNov 25 05:01 ET

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Simply Wall StNov 25 00:22 ET

Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.

①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?

cls.cnNov 19 22:50 ET